Country for PR: Hong Kong
Contributor: PR Newswire Asia (Hong Kong)
Wednesday, May 08 2019 - 12:44
AsiaNet
Kazia calls for greater awareness of the most lethal women's disease in Australia
SYDNEY, May 8, 2019 /PRNewswire-AsiaNet/ --

This World Ovarian Cancer Day, Australian oncology-focused biotech company 
Kazia Therapeutics Ltd (ASX: KZA, NASDAQ: KZIA) calls for greater awareness of 
what is the most lethal women's disease in Australia. 

Logo - https://photos.prnasia.com/prnh/20171120/1996749-1LOGO 

Every year, approximately 1,600 Australian women are diagnosed with ovarian 
cancer[1], most of them at an advanced stage. The disease has the lowest 
survival rate of all female cancers, with only 47.5% of patients surviving five 
years post diagnosis[2].

Kazia's CEO, Dr James Garner said, "Every eight hours in Australia a woman will 
die from ovarian cancer, so we are urging all women to understand all of the 
major signs and symptoms of ovarian cancer and seek regular check-ups with 
their doctors if feeling unwell. 

The four major symptoms of ovarian cancer are feeling full after eating a small 
amount, increased abdominal size or persistent bloating, abdominal or pelvic 
pain and the need to urinate urgently or often. Given these are symptoms common 
to other easily explained conditions means that patients present for diagnosis 
late."

The most commonly reported symptoms are[3]:

- Unexplained fatigue 
- Unexplained weight gain or loss 
- Changes in bowel habits, such as constipation 
- Increased abdominal size or persistent abdominal bloating 
- Abdominal or pelvic (lower tummy) pain 
- Feeling full after eating a small amount 
- Needing to urinate often or urgently

Other signs to watch out for include[4]:

- Abnormal vaginal bleeding 
- Back pain or cramps 
- Indigestion or nausea 
- Excessive fatigue 
- Pain during sex

Sally Goers Fox was diagnosed with ovarian cancer in 2005. She was misdiagnosed 
twice by gynaecologists before her GP  diagnosed her and she went on to be 
treated successfully. She says, looking back, she had ovarian cancer symptoms 
for around 18 months. 

"There needs to be much more education about it. I am well-educated, well read 
and I am an 'on top of my medical stuff kind of person'. I also had breast 
cancer at an early age... so I was on high alert. I didn't know that I had a 
lot of the classic symptoms for ovarian cancer. I just didn't know. 

"[My advice to women is] to dig deeper in terms of learning about the symptoms. 
If you want to arm yourself in the best way, learn a lot more about the 
symptoms than just the typical list that you get."

Kazia Therapeutics is developing a treatment called Cantrixil for ovarian 
cancer, which is currently in phase I human trials in hospitals across 
Australia and the United States. 

The Company recently reported early efficacy results from Part A of the phase I 
study. Of nine patients evaluable for efficacy, five (56%) achieved stable 
disease after two cycles of Cantrixil monotherapy. One of these five patients 
subsequently achieved a partial response when Cantrixil was administered with 
chemotherapy, as intended per protocol.

Cantrixil may provide a new treatment option for women with later-stage ovarian 
cancer, who received limited benefit from existing chemotherapy. Depending on 
clinical trial results, Cantrixil could prolong survival rates for women with 
ovarian cancer by targeting chemotherapy-resistant tumour-initiating cells that 
are thought to be responsible for disease relapse.

For more information on Kazia Therapeutics or Cantrixil, please visit: 
www.kaziatherapeutics.com 

[1] Ovarian Cancer Research Foundation: 
https://ocrf.com.au/about-ovarian-cancer/statistics/
[2] Cancer Australia: https://ovarian-cancer.canceraustralia.gov.au/statistics
[3] Source: Ovarian Cancer Australia: 
https://ovariancancer.net.au/know-ovarian-cancer/signs-and-symptoms/
[4] Source: Marie Claire magazine: 
https://www.marieclaire.com.au/ovarian-cancer-diagnosis

SOURCE  Kazia Therapeutics Limited